Rintaro Noro

Summary

Affiliation: Nippon Medical School
Country: Japan

Publications

  1. doi request reprint MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation
    Rintaro Noro
    Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan
    BMC Cancer 15:31. 2015
  2. pmc Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation
    Rintaro Noro
    Department of Pulmonary Medicine Infection and Oncology, Nippon Medical School, 1 1 5 Sendagi, Bunkyo ku, Tokyo 113 8602, Japan
    BMC Cancer 6:277. 2006
  3. doi request reprint Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model
    Akihiko Miyanaga
    Department of Internal Medicine, Division of Pulmonary Medicine, Infectious Diseases and Oncology, Nippon Medical School, 1 1 5 Sendagi, Bunkyo ku, Tokyo 113 8602, Japan
    Mol Cancer Ther 7:1923-30. 2008
  4. doi request reprint Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression
    Rintaro Noro
    Department of Internal Medicine, Nippon Medical School, Tokyo, Japan
    Cancer Sci 101:1424-30. 2010
  5. ncbi request reprint E-cadherin expression and epidermal growth factor receptor mutation status predict outcome in non-small cell lung cancer patients treated with gefitinib
    Akihiko Miyanaga
    Department of Pulmonary Medicine Infection and Oncology, Nippon Medical School, 1 1 5 Sendagi, Bunkyo ku, Tokyo, Japan
    Oncol Rep 19:377-83. 2008
  6. ncbi request reprint PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors
    Rintaro Noro
    Department of Pulmonary Medicine Infection and Oncology, Nippon Medical School, 1 1 5 Sendagi, Bunkyo ku, Tokyo 113 8602, Japan
    Int J Oncol 31:1157-63. 2007
  7. ncbi request reprint Alternating chemotherapy with amrubicin plus cisplatin and weekly administration of irinotecan plus cisplatin for extensive-stage small cell lung cancer
    Rintaro Noro
    Department of Clinical Oncology, Tokyo Medical University Hospital, 6 7 1, Nishishinjuku, Shinjuku ku, Tokyo, 160 0023, Japan
    Anticancer Res 33:1117-23. 2013
  8. ncbi request reprint In vitro simulation study of individualized chemotherapy in lung cancer
    Cai Li
    Department of Pulmonary Medicine Infection and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan
    J Nihon Med Sch 74:217-22. 2007
  9. pmc MiR-23a regulates TGF-β-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells
    Mengru Cao
    Department of Internal Medicine, Division of Pulmonary Medicine Infection and Oncology, Nippon Medical School, Tokyo 113 8603, Japan
    Int J Oncol 41:869-75. 2012
  10. pmc Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer
    Masaru Matsumoto
    Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, 1 1 5, Sendagi, Bunkyo ku, Tokyo, 113 8603, Japan
    BMC Cancer 15:241. 2015

Collaborators

Detail Information

Publications26

  1. doi request reprint MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation
    Rintaro Noro
    Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan
    BMC Cancer 15:31. 2015
    ....
  2. pmc Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation
    Rintaro Noro
    Department of Pulmonary Medicine Infection and Oncology, Nippon Medical School, 1 1 5 Sendagi, Bunkyo ku, Tokyo 113 8602, Japan
    BMC Cancer 6:277. 2006
    ..However, gefitinib-sensitive and prolonged stable-disease-defined tumors without EGFR gene mutation have also been reported...
  3. doi request reprint Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model
    Akihiko Miyanaga
    Department of Internal Medicine, Division of Pulmonary Medicine, Infectious Diseases and Oncology, Nippon Medical School, 1 1 5 Sendagi, Bunkyo ku, Tokyo 113 8602, Japan
    Mol Cancer Ther 7:1923-30. 2008
    ....
  4. doi request reprint Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression
    Rintaro Noro
    Department of Internal Medicine, Nippon Medical School, Tokyo, Japan
    Cancer Sci 101:1424-30. 2010
    ..We conclude that combination therapy with SAHA and S-1 in lung cancer may be promising due to its potential to overcome S-1 resistance via modulation of 5-FU/S-1 sensitivity-associated biomarker (TS) by HDAC inhibitor...
  5. ncbi request reprint E-cadherin expression and epidermal growth factor receptor mutation status predict outcome in non-small cell lung cancer patients treated with gefitinib
    Akihiko Miyanaga
    Department of Pulmonary Medicine Infection and Oncology, Nippon Medical School, 1 1 5 Sendagi, Bunkyo ku, Tokyo, Japan
    Oncol Rep 19:377-83. 2008
    ..In patients with surgically resected NSCLC tumors, the EGFR mutation status and E-cadherin staining can select patients who will benefit from gefitinib therapy...
  6. ncbi request reprint PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors
    Rintaro Noro
    Department of Pulmonary Medicine Infection and Oncology, Nippon Medical School, 1 1 5 Sendagi, Bunkyo ku, Tokyo 113 8602, Japan
    Int J Oncol 31:1157-63. 2007
    ....
  7. ncbi request reprint Alternating chemotherapy with amrubicin plus cisplatin and weekly administration of irinotecan plus cisplatin for extensive-stage small cell lung cancer
    Rintaro Noro
    Department of Clinical Oncology, Tokyo Medical University Hospital, 6 7 1, Nishishinjuku, Shinjuku ku, Tokyo, 160 0023, Japan
    Anticancer Res 33:1117-23. 2013
    ..A phase II study was conducted in order to determine the tumor efficacy and tolerance of alternating chemotherapy for extensive-stage small cell lung cancer (ED-SCLC)...
  8. ncbi request reprint In vitro simulation study of individualized chemotherapy in lung cancer
    Cai Li
    Department of Pulmonary Medicine Infection and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan
    J Nihon Med Sch 74:217-22. 2007
    ..With elucidation of additional drug sensitivity factors, selection of appropriate anticancer drugs by gene expression profiling may make it possible to increase the response rate in lung cancer chemotherapy...
  9. pmc MiR-23a regulates TGF-β-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells
    Mengru Cao
    Department of Internal Medicine, Division of Pulmonary Medicine Infection and Oncology, Nippon Medical School, Tokyo 113 8603, Japan
    Int J Oncol 41:869-75. 2012
    ..These findings suggest that miR-23a regulates TGF-β-induced EMT by targeting E-cadherin in lung cancer cells and may be useful as a new therapeutic target in NSCLC...
  10. pmc Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer
    Masaru Matsumoto
    Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, 1 1 5, Sendagi, Bunkyo ku, Tokyo, 113 8603, Japan
    BMC Cancer 15:241. 2015
    ..In this study, we analyzed the antitumor effects of mTOR inhibitors in small cell lung cancer (SCLC) cells and sought to clarify the mechanism of resistance to mTOR inhibitors...
  11. doi request reprint MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells
    Kazuhiro Kitamura
    Corresponding Author Masahiro Seike, Nippon Medical School, 1 1 5, Sendagi, Bunkyo ku, Tokyo 113 8603, Japan
    Mol Cancer Ther 13:444-53. 2014
    ..The miR-134/miR-487b/miR-655 cluster may be a new therapeutic target in patients with advanced lung adenocarcinoma, depending on the EMT phenomenon...
  12. pmc Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation
    Akihiko Miyanaga
    Department of Pulmonary Medicine and Oncology, Nippon Medical School, Tokyo, Japan
    BMC Cancer 13:262. 2013
    ..The EML4-ALK fusion gene occurs generally in NSCLC without mutations in epidermal growth factor receptor (EGFR) and KRAS...
  13. ncbi request reprint Phase I/II study of paclitaxel + carboplatin for refractory or recurrent non-small cell lung cancer
    Akihiko Gemma
    Department of Pulmonary Medicine Infection and Oncology, Nippon Medical School, Tokyo, Japan
    Anticancer Res 26:3083-7. 2006
    ..The median survival time was 12 months. This combination showed a promising clinical activity with mild toxicity and should be selected for the investigational arm of phase III trials to be compared with either docetaxel or pemetrexed...
  14. doi request reprint MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma
    Kazuo Yamamoto
    Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo 113 8603, Japan
    Oncol Rep 32:2365-72. 2014
    ..These results suggest that the miR-379/411 cluster may provide new therapeutic opportunities for advanced MPM patients, depending on the nature of IL-18 gene expression...
  15. doi request reprint Clinical features, anti-cancer treatments and outcomes of lung cancer patients with combined pulmonary fibrosis and emphysema
    Yuji Minegishi
    Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, 1 1 5, Sendagi, Bunkyo ku, Tokyo 113 8602, Japan Electronic address
    Lung Cancer 85:258-63. 2014
    ..Nevertheless, the clinical significance of CPFE compared with isolated idiopathic interstitial pneumonias (IIPs) in patients with lung cancer is not well understood...
  16. doi request reprint Inhibition of ABCB1 Overcomes Cancer Stem Cell-like Properties and Acquired Resistance to MET Inhibitors in Non-Small Cell Lung Cancer
    Teppei Sugano
    Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Sendagi, Bunkyo ku, Tokyo, Japan
    Mol Cancer Ther 14:2433-40. 2015
    ..Inhibition of ABCB1 might be a novel therapeutic strategy for NSCLC patients with acquired resistance to MET inhibitors...
  17. doi request reprint Significance of osteopontin in the sensitivity of malignant pleural mesothelioma to pemetrexed
    Susumu Takeuchi
    Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo 113 8603, Japan
    Int J Oncol 44:1886-94. 2014
    ..PEM has antitumor effects in MPM cells dependent on SPP1/OPN overexpression resulting in AKT activation. Our results suggest that SPP1 may be used as a single predictive biomarker of the effectiveness of PEM treatment in MPM. ..
  18. doi request reprint Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion
    Kazuhiro Kitamura
    Division of Pulmonary Medicine, Infection and Oncology, Department of Internal Medicine, Nippon Medical School, 1 1 5 Sendagi, Bunkyo ku, Tokyo 113 8603, Japan
    Cancer Chemother Pharmacol 71:457-61. 2013
    ....
  19. ncbi request reprint Exacerbation of idiopathic interstitial pneumonias associated with lung cancer therapy
    Yuji Minegishi
    Department of Internal Medicine, Nippon Medical School, Tokyo
    Intern Med 48:665-72. 2009
    ..We aimed to identify an appropriate strategy for treatment of this condition. We analyzed clinical features of 120 LC with IIP, retrospectively...
  20. pmc Anticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database
    Akihiko Gemma
    The Fourth Department of Medicine, Nippon Medical School, 1 1 5, Sendagi, Bunkyo ku, Tokyo, 113 8602, Japan
    BMC Cancer 6:174. 2006
    ..It is consequently desirable to find more appropriate therapeutic opportunities based on informed insights. A molecular pharmacological analysis was undertaken to design an improved chemotherapeutic strategy for advanced lung cancer...
  21. ncbi request reprint Successful treatment of histiocytic sarcoma and concurrent HIV infection using a combination of CHOP and antiretroviral therapy
    Kosuke Narita
    Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Japan
    Intern Med 52:2805-9. 2013
    ..The patient has been in complete remission for 12 months following the discontinuation of chemotherapy under continuous ART. This case report may help to promote further investigation of both HS and HIV-related malignancy. ..
  22. pmc Effective Crizotinib schedule for an elderly patient with ALK rearranged non-small-cell lung cancer: a case report
    Aya Fukuizumi
    Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, 1 1 5 Sendagi, Bunkyo ku, Tokyo, 113 8602, Japan
    BMC Res Notes 8:165. 2015
    ..Non-small-cell lung cancers (NSCLCs) harboring translocations in anaplastic lymphoma kinase (ALK) are highly sensitive to small-molecule ALK kinase inhibitors, such as crizotinib...
  23. doi request reprint A case of pneumocystis pneumonia associated with everolimus therapy for renal cell carcinoma
    Yoshinobu Saito
    Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan, Japan
    Jpn J Clin Oncol 43:559-62. 2013
    ....
  24. ncbi request reprint [EGFR and gefitinib (Iressa)]
    Rintaro Noro
    Division of Pulmonary Medicine, Infectious Disease, and Oncology, Dept of Internal Medicine, Nippon Medical School, Tokyo, Japan
    Gan To Kagaku Ryoho 35:1076-9. 2008
    ..3%, in the USA(FDA Approval Letter). Further studies about the prediction of drug-induced interstitial lung disease including SNPs analyses of the EGFR gene and other related molecules...
  25. doi request reprint Phase II study of carboplatin, docetaxel and bevacizumab for chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer
    Yuichi Takiguchi
    Department of Medical Oncology, Graduate School of Medicine, Chiba University, 1 8 1, Inohana, Chuo Ku, Chiba, 260 8670, Japan
    Int J Clin Oncol 20:659-67. 2015
    ..To evaluate a 3-drug combination of carboplatin, docetaxel and bevacizumab as a front-line chemotherapy for patients with advanced non-squamous non-small cell carcinoma (NSCLC), a single arm phase II study was conducted...
  26. pmc Prognostic significance of PIK3CA and SOX2 in Asian patients with lung squamous cell carcinoma
    Yoshihito Iijima
    Department of Thoracic Surgery, Graduate School of Medicine, Nippon Medical School, Tokyo 113 8603, Japan
    Int J Oncol 46:505-12. 2015
    ..Classification by PIK3CA and SOX2 protein expression is useful for predicting the prognosis of Asian patients with lung SQCC with stage I...